ENCEL, a new drug development company, announced on the 27th that it has signed an additional contract for consignment development and production (CDMO) for clinical research on advanced regenerative medicine with Asan Medical Center in Seoul. ENCEL has been supplying clinical research and advanced regenerative care-related cells to the hospital since 2023. ENCell believes that this additional contract has enabled continuous and stable cell supply.

ENCEL expects to further expand patient-specific treatment opportunities through the Advanced Regenerative Medicine Act revised on the 21st of last month. We are working with large medical institutions to conduct consulting for advanced regenerative clinical research and treatment as well as cell production, a company official said. "We will speed up further collaboration to preemptively enter the market in the advanced regenerative medical industry."

[Reporter Kim Jihee]